The United States Eventing Association (USEA) is pleased to announce the renewal of its partnership with PulseVet, a division of Zomedica Inc., as a corporate sponsor for the 2025 season. PulseVet will continue its role as the “Official Shock Wave of the USEA”, marking the second year of a dynamic partnership that highlights a shared commitment to equine health and performance.
Zomedica Incorporated acts as the parent company of PulseVet, who is a leading provider of veterinary shock wave therapy for the treatment of a wide variety of conditions in horses, including soft tissue injuries, bone healing, and chronic lameness. Backed by strong clinical evidence and used by top veterinarians around the world, PulseVet’s advanced technology promotes healing and enhances performance in a non-invasive, drug-free way. This partnership highlights advanced regenerative therapies that can help USEA members keep their horses healthy, sound, and performing at their best.
“We are incredibly proud to partner with the United States Eventing Association as the official shock wave partner,” said Courtney Calnan, Senior Product Manager at Zomedica “Our commitment to advancing equine health and performance aligns perfectly with the values of the USEA and the dedication of its members. Through this sponsorship, we look forward to supporting the eventing community and helping equine athletes perform at their peak while staying healthy and sound.”
For the 2025 competition season, PulseVet will support the USEA across multiple initiatives, including as a Gold Level Sponsor of the USEA American Eventing Championship (AEC) presented by Nutrena Feeds, Contributing Sponsor of the USEA Adult Team Championships (ATC), Bronze Sponsor of the USEA Classic Series, Contributing Sponsor of the USEA Intercollegiate & Interscholastic Championships (IEL), and Contributing Sponsor of the USEA Annual Meeting & Convention.
As part of their partnership, PulseVet will award prize certificates to the top 3 teams in each division at the Intercollegiate & IEL League Championships. In addition, Assisi Loops, an innovative, non-invasive PEMF therapy product under the Zomedica umbrella, will be presented as prizes for the USEA Classic Series year-end sweepstake.
“We are thrilled to welcome PulseVet back for another exciting season,” said Rob Burk, USEA CEO. “Their technology is innovative, and their commitment to equine health makes them a valuable partner to our members and their horses.”
For more information on PulseVet and their veterinary shock wave technology, visit www.pulsevet.com.
About the United States Eventing Association
The USEA is a non-profit 501(c)(3) educational organization committed to providing eventing enthusiasts with a competitive level suited to their individual skills. By assisting and educating competitors, event organizers, and officials; maintaining responsible safety standards; and registering qualified competitions and clinics, the USEA offers a strong and continuous training opportunity for an ever-expanding field of world-class competitors. Just as importantly, the USEA provides a means for all riders, regardless of age or ability, to experience the thrill of eventing. To learn more, visit www.useventing.com.
Whether you've brought your horse up from Novice or took on the ride later in their career, getting to your first five-star on a special partner is a huge accomplishment.
Are you following along with the action from home this weekend? Or maybe you're competing at an event and need information fast. Either way, we’ve got you covered!
The United States Eventing Association, Inc. (USEA) is excited to announce that Stable View has been selected as the host venue for the first standalone USEA Intercollegiate & Interscholastic Eventing Championships which will take place in 2026 and 2027.
The U.S. Equestrian Federation (USEF), in collaboration with the United States Eventing Association (USEA), has announced a new national review process for innovative frangible cross-country jump designs. This initiative aims to support and streamline the evaluation and potential use of novel frangible devices at the national level within the United States.